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More than one million patients were diagnosed with invasive
breast cancer worldwide in 2000.1 In the current era of mam-
mographic detection, most of these patients were diagnosed
with early-stage disease.2,3
Preoperative chemotherapy, also called neoadjuvant, in-
duction or primary chemotherapy, is recognized as standard
therapy for patients with locally advanced breast cancer. More
recent clinical trials have examined the potential benefits of
preoperative chemotherapy in patients with early-stage breast
cancer (stages I–IIB).4,5 There are a number of potential advan-
tages for administering preoperative chemotherapy to this
patient population. First, several studies have demonstrated
that it is possible to achieve a substantial reduction in the size
of the primary tumour as well as nodal metastases in up to 80%
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of patients after only three to four cycles of chemotherapy.6
With a decrease in the size of the primary tumour, there is a
greater probability that breast-conserving surgery can be
performed.6–9 Another advantage of preoperative chemo-
therapy is that it permits the in vivo assessment of tumour
response to a particular chemotherapy regimen.10
Sentinel lymph node biopsy can accurately determine tu-
mour spread to the regional lymph nodes and is rapidly replac-
ing traditional axillary lymph node dissection as the primary
staging modality for patients with early-stage breast cancer.11
The reported identification rates and false-negative rates with
sentinel lymph node biopsy in patients who have not received
preoperative chemotherapy range from 84–100% and 0–13%,
respectively.12,13
The questions of whether sentinel lymph node biopsy is
feasible and accurate after preoperative chemotherapy are
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critical since the sequencing of chemotherapy first followed by
surgery has been proposed as the new paradigm in breast can-
cer treatment. Some clinicians have postulated that lymphatic
mapping may not be successful after preoperative chemo-
therapy because of excessive fibrosis of the primary tumour
and lymphatics and/or blockage of lymphatic channels with
cellular material or tumour emboli.10,14 The objective of this
review was to identify and summarize the findings of pub-
lished clinical studies that have examined the results of senti-
nel lymph node biopsy following preoperative chemotherapy
and to provide recommendations for its use in clinical practice.
Published clinical studies
Relevant studies available for review as of June 2003 were
identified through MEDLINE (1990 to June 2003) and Can-
cerlit (to October 2002). Subject headings used to perform
the searches were “breast neoplasms”, “sentinel lymph node
biopsy” and “neoadjuvant therapy” including all subheadings.
Studies examining the results of sentinel lymph node biopsy
following preoperative chemotherapy in patients with oper-
able breast cancer were included in the analysis. The accuracy
of sentinel lymph node biopsy is measured primarily by exam-
ining the false-negative rate. This is determined by evaluating
the histological results of the sentinel lymph node in conjunc-
tion with the histological results of axillary lymph node dis-
section (the gold standard). A false-negative event occurs
when the sentinel lymph node is histologically negative for
metastasis but one or more of the axillary lymph nodes is
found to contain metastatic disease.
There are published data from 10 non-randomized stud-
ies15–24 and one large randomized trial (National Surgical
Adjuvant Breast and Bowel Project, NSABP, B-27 trial)25 that
have examined the accuracy of sentinel lymph node biopsy
following preoperative chemotherapy in a total of 738 pa-
tients (Table 1). Most of the studies (82%) were conducted in
single institutions,15–18,20–24 two were based on a single sur-
geon’s experience22,23 and two were multicentre trials.19,25
Three of the studies included data for comparison from groups
of patients with breast cancer who did not receive preoperative
chemotherapy;16,17,19 three studies collected patient data
prospectively.19,20,25 Sample sizes for the preoperative chemo-
therapy groups ranged from 14 to 420 patients.
The methods of sentinel lymph node detection included
combination radioactive isotope and blue dye, isotope
alone and blue dye alone (Table 2). Clinical stage ranged from
I to IIIB, but was not reported in all studies. Various chemo-
therapy combinations were used, with most patients receiv-
ing anthracycline-based regimens (Table 2). The reported
clinical response rates (partial or complete) ranged from 57–
Table 1. Descriptions of 11 studies published from 2000–2003
Authors  Year Study design Study period Setting N  
                Treatment group
Preop chemo No chemo
Breslin et al [15] 2000 Retrospective consecutive 1994–1999 Single institution 151 151 NA
Nason et al [16] 2000 Retrospective cohort with 10/1996–06/1999 Single institution 182 115 67
   comparison 1
Fernandez et al [17] 2001 Retrospective cohort with NA Single institution 176 140 36
   comparison
Haid et al [18] 2001 Retrospective consecutive NA Single institution 133 133 NA
Tafra et al [19] 2001 Retrospective cohort with 02/1997–03/2001 Multicentre trial (private practice 968 129 939
   comparison    and academic centre)
Balch et al* [20] 2002 Consecutive data from 07/1997–08/2001 Single institution 126 126 NA
   prospective clinical trial
Mamounas et al* [25] 2002 Consecutive data from 01/1996–12/2000 Multicentre trial NSABP B-27 420 420 NA
   prospective clinical trial
Stearns et al [21] 2002 Retrospective consecutive 11/1997–07/2000 Single institution 134 134 NA
Brady [22] 2002 Retrospective consecutive 02/1998–07/2000 Single surgeon 114 114 NA
Julian et al [23] 2002 Retrospective consecutive 05/1997–03/2002 Single surgeon 134 134 NA
Piato et al [24] 2003 Retrospective consecutive NA Single institution 142 142 NA
*Abstract only. Preop chemo = preoperative chemotherapy; No chemo = no preoperative chemotherapy; NA = not available; NSABP B-27 = National Surgical Adjuvant Breast
and Bowel Project B-27 trial.
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Table 2. Influence factors
                         Staging               Primary tumour response rate
Authors SNB method     T      Stage Neoadjuvant therapy Clinical Pathological
CR PR NR CR
Breslin et al [15] Dye 45% (23/51) T1 (NA) IIA: 49% (25/51) FAC: 69% (35/51) NA 98% (40/41) 2% (1/41) NA
Dye + Isotope 55% T2 (NA) IIB: 24% (12/51) High-dose FAC: 4% (2/51)
   (28/51) T3 (NA) IIIA: 27% (14/51) Paclitaxel + FAC: 15% (8/51)
AT: 10% (5/51)
Tamoxifen: 2% (1/51)
Nason et al [16] Dye (NA) T2 (NA) NA AC 15% (2/13) 62% (8/13) 23% (3/13) NA
Isotope (NA) T3 (NA)
Dye + Isotope (NA)
Fernandez et al Isotope 100% T1: 10% (4/40) I: 10% (4/40) NA NA NA NA NA
[17]    (40/40) T2: 42.5% (17/40) IIA: 25% (10/40)
T3: 40% (16/40) IIB: 47.5% (19/40)
T4: 7.5% (3/40) IIIA: 10% (4/40)
IIIB: 7.5% (3/40)
Haid et al [18] Dye + Isotope 100% T1: 6% (2/33) NA CMF, EC, TE 37% (12/33) 33% (11/33) 30% (10/33) 9% (3/33)
   (33/33) T2: 91% (30/33)
T3: 3% (1/33)
Tafra et al [19] Dye + Isotope 100% NA NA NA NA NA NA NA
   (29/29)
Balch et al [20] Dye + Isotope 100% T2 (NA) II: 50% (13/26) AC or FAC : 81% (21/26) NA 85% (22/26) NA 8% (2/26)
   (26/26) T3 (NA) III: 50% (13/26) Paclitaxel and RT: 19% (5/26)
T4 (NA)
Mamounas et al Dye 30% (126/420) NA NA AC or AC + T NA NA NA 18% (56/312)
[25] Isotope 16% (67/420)
Dye + Isotope 54%
   (227/420)
Stearns et al [21] Dye (NA) T3: 74% (25/34) NA AC: 21% (7/34) NA NA NA NA
Isotope (NA) T4: 26% (9/34) A + paclitaxel ± C: 70% (24/34)
Dye + Isotope (NA) AC + paclitaxel/trastuzumab: 3% (1/34)
Endocrine: 6% (2/34)
Brady [22] Dye 93% (13/14) NA I: 7% (1/14) AC: 72% (10/14) 14% (2/14) 43% (6/14) 43% (6/14) NA
Dye + Isotope 7% IIA: 36% (5/14) AC + T: 14% (2/14)
   (1/14) IIB: 29% (4/14) AC + paclitaxel: 7% (1/14)
IIIA: 14% (2/14) AC + paclitaxel/trastuzumab: 7% (1/14)
IIIB: 14% (2/14)
Julian et al [23] Dye (NA) T1 (NA) I–IIIA AC: 74% (25/34) 59% (20/34) 12% (4/34) 29% (10/34) 18% (6/34)
Isotope (NA) T2 (NA) AC + T: 26% (9/34)
Dye + Isotope (NA) T3 (NA)
Piato et al [24] Isotope 100% T1: 60% (25/42) I–II AC 45% (19/42) 50% (21/42) 5% (2/42) NA
    (42/42) T2: 40% (17/42)
SNB = sentinel node biopsy; CR = complete response; PR = partial response; NR = no response; NA = not available; FAC = fluorouracil/doxorubicin/cyclophosphamide;
AT = doxorubicin/docetaxel; AC = doxorubicin/cyclophosphamide; CMF = cyclophosphamide/methotrexate/fluorouracil; EC = epirubicin/cyclophosphamide;
TE = docetaxel/epirubicin; RT = radiotherapy; T = docetaxel; A = doxorubicin; C = cyclophosphamide.
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Table 3. Test characteristics of sentinel node biopsy after preoperative chemotherapy
Authors Identification rate False-negative rate Sensitivity Specificity Positive predictive Negative predictive Overall accuracy
n (%) n (%) n (%) n (%) value, n (%) value, n (%) n (%)
Breslin et al [15] 43/51 (84) 3/25 (12) 22/25 (88) 18/18 (100) 22/22 (100) 18/21 (86) 40/43 (93)
Nason et al [16] 13/15 (87) 3/9 (33) 6/9 (67) 4/4 (100) 6/6 (100) 4/7 (57) 10/13 (77)
Fernandez et al [17] 34/40 (85) 4/20 (20) 16/20 (80) 14/14 (100) 16/16 (100) 14/18 (77) 30/34 (88)
Haid et al [18] 29/33 (88) 0/18 (0) 18/18 (100) 11/11 (100) 18/18 (100) 11/11 (100) 29/29 (100)
Tafra et al [19] 27/29 (93) 0/26 (0) 26/26 (100) NA NA NA NA
Balch et al [20] 25/26 (96) 1/14 (7) 13/14 (93) 11/11 (100) 13/13 (100) 11/12 (92) 24/25 (96)
Mamounas et al [25] 357/420 (85) 15/138 (11) 123/138 (89) 202/202 (100) 123/123 (100) 202/217 (93) 325/340 (96)
Stearns et al [21] 23/26 (88) 1/16 (6) 15/16 (94) 7/7 (100) 15/15 (100) 7/8 (88) 22/23 (96)
Brady [22] 13/14 (93) 0/10 (0) 10/10 (100) 3/3 (100) 10/10 (100) 3/3 (100) 13/13 (100)
Julian et al [23] 31/34 (91) 0/12 (0) 12/12 (100) 19/19 (100) 12/12 (100) 19/19 (100) 31/31 (100)
Piato et al [24] 41/42 (98) 3/18 (17) 15/18 (83) 23/23 (100) 15/15 (100) 23/26 (88) 38/41 (93)
NA = not available.
98%.15,16,18,20,22–24 Pathological complete response was reported
in four studies and ranged from 8–18%.18,20,23,25
Test characteristics
Relevant test characteristics for sentinel node biopsy (SNB)
were calculated or recalculated for the published trials using
the following formulas:
• Identification rate = patients with successful SNB/patients
undergoing SNB
• False-negative rate = false negatives/(true positives + false
negatives)
• Sensitivity = true positives/(true positives + false negatives)
• Specificity = true negatives/(true negatives + false positives)
• Positive predictive value = true positives/(true positives +
false positives)
• Negative predictive value = true negatives/(true negatives +
false negatives)
• Overall accuracy = (true positives + true negatives)/pa-
tients with successful SNB
A true positive was defined as a node positive on both SNB
and axillary lymph node dissection, a false positive as a node
positive on SNB and negative on axillary lymph node dissection,
a true negative as a node negative on both SNB and axillary
lymph node dissection, and a false negative as a node negative
on SNB and positive on axillary lymph node dissection.
The test characteristics of SNB following preoperative
chemotherapy in patients with operable breast cancer are
outlined in Table 3. Ten of the 11 studies demonstrated
favourable results, with overall accuracy ranging from 88–
100%.15,17–25 The identification rate of sentinel lymph nodes
following preoperative chemotherapy was 84–98%. The false-
negative rates ranged from 0–20%. The remaining study by
Nason et al reported a false-negative rate of 33% and an over-
all accuracy of 77%.16 This study was limited in that only nine
of 15 patients had positive lymph nodes and three of these
patients had a false-negative sentinel lymph node. The ability
of such a small study to define the accuracy of sentinel lymph
node biopsy following chemotherapy is highly questionable.
Discussion
While neoadjuvant chemotherapy is currently considered the
standard of care for patients with locally advanced breast
cancer, the indications for its use in patients with early-stage
disease are still evolving. The primary rationale is earlier treat-
ment of occult systemic metastases; however, trials directly
comparing neoadjuvant with adjuvant chemotherapy have
not conclusively demonstrated a survival advantage for pa-
tients treated with the neoadjuvant approach. Patients treated
with chemotherapy first are more likely to be candidates for
breast-conserving surgery and less likely to have positive lymph
nodes.6
Based on the available literature, it appears that lymphatic
mapping and sentinel lymph node biopsy after neoadjuvant
chemotherapy for breast cancer are both feasible and accurate.
Most studies to date are retrospective and include a heteroge-
neous patient population treated with different chemotherapy
drugs and treatment schedules. Thus far, the combination
approach using blue dye with radioisotope resulted in maxi-
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mum sentinel node identification rates. With the exception of
Nason et al’s report,16 the false-negative rates are comparable
to early reports of SNB in early-stage untreated breast cancer
patients.
Since the fibrotic response to chemotherapy in treated
breast tissue and nodal basins is known to result in increased
difficulty with surgical dissection and pathological assess-
ment of tissues, the learning curve may be different for sur-
geons attempting sentinel lymph node biopsy in patients
treated with neoadjuvant chemotherapy compared with sur-
geons performing it in untreated patients. It would seem
prudent that each individual surgeon examine their cases of
sentinel lymph node biopsy after chemotherapy separately
from those patients treated with surgery first, in order to
evaluate his or her learning curve.
There are a number of clinical questions that must be
addressed in future clinical trials. Is complete axillary node
dissection necessary in patients with micrometastatic disease
in the sentinel node? The American College of Surgeons On-
cology Group Trial Z0011 was designed to specifically address
this question. It is actively accruing patients but is unlikely to
provide a definitive answer for another 5 years. Several groups,
including our own here at the M.D. Anderson Cancer Center,
have developed models based on clinical and pathological
factors to determine the likelihood that a patient with disease
in the sentinel node will harbour additional disease in the
remaining axillary lymph nodes.26 While these tools may be
useful for patients treated with surgery first, it is unlikely that
they will be immediately translated into a prognostic model
for patients treated with neoadjuvant chemotherapy prior to
surgery.
Another critical question is whether or not axillary irradia-
tion can be used as the sole form of local treatment of the axilla
in select patient populations. Several studies have been pub-
lished on the use of axillary irradiation in clinically node-
negative breast cancer patients and demonstrate failure rates
of 1–2%.27 In patients treated with breast-conserving surgery,
tangential breast irradiation will include most of the sentinel
node dissection field and, in fact, includes about one-third to
two-thirds of the level I and level II axillary lymph nodes.28
Although there is less experience with radiation therapy in
the treatment of the clinically node-negative axilla following
neoadjuvant chemotherapy, there are sufficient data to sup-
port the use of radiation therapy as an adjunct to SNB in
this patient population.
As the use of neoadjuvant chemotherapy continues to
increase in the treatment of breast cancer patients, it is impor-
tant that we carefully assess the role of SNB in these patients.
Just as breast-conserving surgery is now an accepted treat-
ment modality for selected patients following neoadjuvant
chemotherapy, there will be a role for SNB as well. Single-
institution studies will provide useful information; however,
national trials with multiple participating institutions will
ultimately be needed in order to clearly define this role.
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